Top 25 of the most highly down-regulated genes between COPD patients with acute exacerbation vs stable COPD patients

Top 25 of the most highly up-regulated genes between COPD patients with acute exacerbation vs stable COPD patients

Table 3. Fold-change on cDNA microarray for selected genes

Table 2. Fold-change for individual genes from the gene set \Proteinaceous Extracellular Matrix\""

Table 3. Differentiate expressed miRNAs identified in NSCLC and their target prediction

GSE3494 ER Predictor Gene List; The ER predictor was based on 1 022 probe sets identified by a Wilcoxon rank sum test with Bonferroni correction (adjusted P<.05)  with intentional exclusion of probe sets for ER itself

GSE1456 Recurrence Predictor Gene List; A total of 205 probe sets (representing 184 genes) identified with a false discovery rate < 0.01. These probe sets contain an over-representation of genes involved in cell cycles (20 genes; P < .001)  cytokinesis (seven genes; P = .004)  and cellular metabolism (84 genes; P = .004)

Docetaxel Chemosensitivity Signature Gene List

Adriamycin Chemosensitivity Signature Gene List

Table 1. List of the genes that were up- or down-regulated by maspin

Table S2. List of LSC signature genes; genes with expression levels
significantly higher in LSCs than in HSCs and genes that were highly expressed in LSCs but showed minimal expression in HSCs

Table S5. Ninety one top-ranked genes used for recurrence prediction analysis in nontumoral samples from late (>1 year) recurrence subjects

Table S1. Top scoring pairs for classification of the primary prostate tumors and distant metastases (DM)

Table S1 Annotated genes with down-regulated expression in PTP1B?siRNA-treated cells compared with control?siRNA-treated cells

Table S2 Annotated genes with up-regulated expression in PTP1B?siRNA-treated cells compared with control?siRNA-treated cells

Table 1b. Summary of downregulated miRNAs in SCs and gliomas

Table 1a. Summary of upregulated miRNAs in SCs and gliomas

Table S1. List of identified 107 genes up- and downregulated by more than 1.5-fold in IFN-resistant cells (PLC-R1  PLC-R2  and PLC-R3) with parental cells (PLC-P)